Journal of Sleep Disorders & Therapy
Open Access

Respicardia, Inc, 12400 Whitewater Dr #150, Minnetonka, MN, United States

Biography

Dr. Scott McKane, Completed his MS. Statistics at Iowa State University in the year 2000. Previously he worked as Senior Principal Statistician and Data Management at Minnetonka, Minnesota and he is currently working as Director, Clinical Operations at ZOLL Respicardia.

Publications

• Case Report   
  Transvenous Phrenic Nerve Stimulation and Automatic Positive Airway Pressure Therapy for Treating Central Sleep Apnea and Residual Obstructive Sleep Apnea
  Author(s): Daniel Beyerbach, Jill Fricke, Kris James, Scott McKane and Karthik Kanagarajan*
  
  Central sleep apnea (CSA) is a neurological breathing disorder resulting from intermittent disruptions in the neural drive to breath. CSA and obstructive sleep apnea (OSA), caused by partial or complete airway blockage, sometimes occur together. The remede System (Respicardia, Minnetonka, MN) is an implantable device that delivers transvenous phrenic nerve stimulation therapy (TPNS) to treat CSA. A patient who failed previous Positive Airway Pressure (PAP) therapies presented with severe CSA and OSA with a baseline Apnea Hypopnea Index (AHI) of 98.1 events/hour. The patient was implanted with a TPNS device and titrated to maximum effectiveness. His CSA improved, but still had persistent OSA. PAP therapy was added to supplement the TPNS. With TPNS off, PAP therapy treated obstructive events but not the central events. TPNS alone treated the central events but not the obstructive events.. View More»
  DOI: 10.35248/2167-0277.20.9.311

  Abstract HTML PDF